Waldenstrom macroglobulinemia is considered the most common subtype of lymphoplasmacytic lymphoma, as per the current WHO classification. Although a rare blood cancer, the incidence of Waldenstrom’s macroglobulinemia is strongly influenced by sex, age, race, and ethnicity. It is reported that the incidence of Waldenstrom’s macroglobulinemia is two times higher in men than in women in the United States. Existing treatments for this B-cell lymphoma are often linked to significant side effects, indicating the need for therapies with improved safety profiles and better tolerability.
Major companies involved in Waldenstrom’s macroglobulinemia pipeline drugs market include Merck Sharp & Dohme LLC and Schrodinger Inc., among others.
Leading drugs currently under the pipeline include Iopofosine I 131 (CLR 131) and SGR-1505, among others.
The growing focus on the development of drug candidates that provide sustained disease control without continuous treatment is likely to positively influence the pipeline landscape for Waldenstrom macroglobulinemia.
Waldenstrom’s Macroglobulinemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Waldenstrom’s macroglobulinemia drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Waldenstrom’s macroglobulinemia. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The Waldenstrom’s macroglobulinemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Waldenstrom’s Macroglobulinemia.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Waldenstrom’s macroglobulinemia.
Waldenstrom’s macroglobulinemia refers to a type of non-Hodgkin lymphoma that affects plasma cells and lymphoplasmacytoid cells (types of white blood cells). It is caused by DNA changes in the white blood cells that trigger them to multiply quickly and live longer than healthy cells. Common symptoms of this rare, slow-growing blood cancer include extreme tiredness, nosebleeds, frequent infections, and unintentional weight loss, among others.
Waldenstrom’s macroglobulinemia is treated by a combination of drugs, procedures, and other therapies. Chemotherapy, radiation therapy, and plasmapheresis are common treatment options for this rare disease. Steroids such as dexamethasone or prednisolone are often prescribed to increase the efficiency of chemotherapy agents. However, certain patients develop resistance to current therapies, leading to disease progression or relapse. Thus, there is a critical need to develop novel drugs that target alternative pathways or overcome resistance mechanisms.
This section of the report covers the analysis of Waldenstrom’s macroglobulinemia drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for Waldenstrom’s macroglobulinemia.
The drug molecule categories covered under Waldenstrom’s macroglobulinemia pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Waldenstrom macroglobulinemia.
The EMR report for Waldenstrom’s macroglobulinemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Waldenstrom’s macroglobulinemia clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Cellectar Biosciences, Inc., the objective of this Phase 2, open-label, multicenter study is to evaluate Iopofosine I 131 (CLR 131), a targeted radiotherapeutic, in patients with relapsed or refractory (R/R) B-cell cancers and in an expansion group of patients with Waldenstrom macroglobulinemia. The study is expected to be completed by December 2026 and has an estimated 120 participants.
Schrödinger, Inc. is conducting a Phase 1 dose-escalation study aimed at evaluating an oral inhibitor of MALT1 called SGR-1505 in participants with B-cell malignancies including Waldenstrom macroglobulinemia. The interventional study has enrolled an estimated 52 subjects and is expected to be completed by March 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Waldenstrom’s Macroglobulinemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Waldenstrom’s macroglobulinemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Waldenstrom’s macroglobulinemia pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share